欧盟HTA法规和联合临床评估-威胁还是机遇?
1SAI MedPartners, Reading, PA 19606, USA; vschuster@sai-med.com.
Journal of market access & health policy
|May 29, 2024
概括
新的欧盟HTA法规旨在协调临床评估,但可能会造成官僚主义. 制造商在联合临床评估 (JCA) 过程中面临新的挑战和机遇.
科学领域:
- 卫生政策和监管卫生政策和监管
- 药品市场准入 药品市场准入
- 医疗技术评估 医学技术评估
背景情况:
- 欧盟 (EU) 旨在统一卫生技术评估 (HTA) 流程,以协调临床数据评估,防止冗余的努力.
- 新的2022年欧盟HTA法规旨在使这些雄心壮志成为正式目标,以便在成员国之间采取更简单的方法.
- 行业前景表明潜在的风险,包括增加的官僚主义,评估延迟和额外的档案提交要求,可能会重复国家一级的HTA努力.
研究的目的:
- 批判性地研究新的欧盟HTA法规对制药和医疗器械制造商的影响.
- 分析联合临床评估 (JCA) 过程带来的具体挑战和潜在好处.
- 确定新监管框架所带来的欧盟和附属机构层面的机遇和威胁.
主要方法:
- 对欧盟HTA条例文本和声明目标的定性分析.
- 审查行业专家意见和对监管途径的潜在影响.
- 对拟议的欧盟级HTA程序与现有的国家HTA要求进行比较评估.
主要成果:
- 欧盟HTA法规引入了一个联合临床评估 (JCA) 机制,旨在协调临床数据评估.
- 制造商可能会面临更多的行政负担和需要在国家提交文件之外,在欧盟一级新文件.
- 根据实施情况,有可能在某些领域简化市场准入,而在其他领域增加复杂性和延迟.
结论:
- 欧盟HTA法规对制造商来说是一个双刃剑,它提供了协调潜力,同时也带来了官僚障碍的风险.
- 对制造商来说,有效的JCA流程导航对于利用机会和减轻威胁至关重要.
- 长期影响将取决于欧盟HTA作为"学习系统"的实际实施和发展.
相关概念视频
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Clinical Trials
6.7K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.7K
Drug Control Governance: Regulatory Bodies and Their Impact
156
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
156
Nursing Assessment
7.5K
The two sources for collecting information are primary and secondary. After gathering information, interpretation and validation help to complete the data. The purpose of assessment is to establish data with the initial information, to interpret data about the patient's perceived needs and health problems, and to respond to these problems identified.
The nurse collects all aspects of the patient's health in the initial assessment, establishing priorities for ongoing focused assessments...
The nurse collects all aspects of the patient's health in the initial assessment, establishing priorities for ongoing focused assessments...
7.5K
Standards of Care II
641
Nurses bear specific legal responsibilities under several federal statutes, including:
641
Hazard Ratio
114
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
114


